Karl S. Peggs

Q: What Schools Are Affiliated With Karl S. Peggs

Karl S. Peggs is affiliated with the following schools: University of Oxford, University College London

Karl S. Peggs's AcademicInfluence.com Rankings

Karl S. Peggs

Biology

#13223

World Rank

#16757

Historical Rank

Immunology

#906

World Rank

#929

Historical Rank

biology Degrees

Download Badge

Biology

Karl S. Peggs's Degrees

PhD Immunology University of Oxford
Bachelors Biochemistry University of Oxford

Why Is Karl S. Peggs Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Karl S. Peggs's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. (2018) (1270)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013) (1191)
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution (2017) (1092)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009) (830)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010) (748)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells (2017) (667)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. (2006) (653)
Checkpoint blockade in cancer immunotherapy. (2007) (528)
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines (2003) (458)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. (2006) (438)
Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. (2015) (432)
Epitope landscape in breast and colorectal cancer. (2008) (396)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (2018) (376)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. (2002) (362)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. (2002) (361)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (292)
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. (2004) (289)
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (2005) (273)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. (2014) (261)
Diagnosis of Neuroinvasive Astrovirus Infection in an Immunocompromised Adult With Encephalitis by Unbiased Next-Generation Sequencing (2015) (238)
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication (2011) (237)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. (2005) (235)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. (2005) (226)
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. (2004) (222)
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma (2008) (214)
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy (2008) (212)
Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. (2011) (210)
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study (2014) (208)
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. (2003) (188)
Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. (2003) (169)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (154)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies (2017) (153)
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. (2009) (151)
Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. (2016) (149)
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer (2013) (148)
Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists (2009) (143)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (141)
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. (2010) (135)
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report (2015) (130)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2019) (119)
Background to hematopoietic cell transplantation, including post transplant immune recovery (2009) (117)
Guidelines for the management of diffuse large B‐cell lymphoma (2016) (116)
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma (2005) (114)
Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation (2011) (111)
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. (2017) (110)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2019) (110)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (109)
Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes (2007) (109)
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. (2008) (108)
The incidence and cause of coagulopathies in an intensive care population (1996) (108)
Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. (2008) (107)
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. (2011) (105)
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation (2008) (101)
The function and dysfunction of memory CD8+ T cells in tumor immunity (2018) (100)
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas (2013) (97)
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. (2010) (93)
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. (2003) (92)
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. (2015) (91)
First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL (2015) (90)
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. (2014) (90)
Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. (2009) (89)
Management of cytomegalovirus infection in haemopoietic stem cell transplantation (2013) (85)
Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells (2020) (80)
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols (2016) (79)
Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. (2002) (79)
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy (2015) (72)
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia (2010) (72)
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma (2017) (71)
Immune reconstitution following haematopoietic stem cell transplantation (2004) (63)
Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation (2000) (63)
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. (2018) (62)
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. (2007) (60)
TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. (2016) (59)
A clonal expression biomarker associates with lung cancer mortality (2019) (59)
The T cell differentiation landscape is shaped by tumour mutations in lung cancer (2020) (59)
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. (2010) (58)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. (2010) (58)
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily (2005) (57)
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity (2020) (56)
Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis (2018) (55)
Immunotherapy for transplantation-associated viral infections (2017) (54)
Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. (2003) (54)
Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning (2013) (52)
TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. (2015) (52)
T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions (2003) (51)
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. (2008) (46)
Adoptive T cell immunotherapy for cytomegalovirus (2009) (44)
In vitro comparison of currently available and investigational antiviral agents against pathogenic human double‐stranded DNA viruses: A systematic literature review (2019) (42)
First Reported Outbreak of Diarrhea Due to Adenovirus Infection in a Hematology Unit for Adults (2005) (39)
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. (2020) (38)
Cellular therapy: donor lymphocyte infusion (2001) (38)
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status. (2015) (38)
Tumour heterogeneity and immune-modulation (2013) (38)
The role of allogeneic transplantation in non‐Hodgkin's lymphoma (2005) (37)
Assessing diversity: immune reconstitution and T‐cell receptor BV spectratype analysis following stem cell transplantation (2003) (37)
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation. (2006) (37)
Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 (2005) (36)
CMV-specific cellular therapy for acute myeloid leukemia? (2012) (35)
Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party (2018) (35)
Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia (2013) (34)
Management of multidrug‐resistant viruses in the immunocompromised host (2012) (34)
Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. (2004) (33)
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma (2010) (30)
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma (2014) (30)
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment (2018) (29)
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma (2003) (29)
Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans. (2006) (28)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma (2018) (28)
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. (2012) (28)
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure (2014) (27)
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. (2006) (26)
Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4 (2018) (26)
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. (2016) (26)
Therapeutic strategies for the prevention and treatment of cytomegalovirus infection (2012) (25)
Allogeneic transplantation for Hodgkin lymphoma (2008) (23)
Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma. (2003) (23)
Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. (2015) (23)
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience (2012) (22)
Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. (2011) (22)
Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation (2009) (22)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (2021) (22)
Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation. (2004) (22)
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party (2018) (21)
Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (2017) (20)
Evolving adoptive cellular therapies in urological malignancies. (2017) (20)
Using DNA sequencing data to quantify T cell fraction and therapy response (2021) (19)
The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. (2012) (18)
Immune Reconstitution following Stem Cell Transplantation (2004) (18)
Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting (2017) (17)
Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes (2017) (17)
Imatinib mesylate—gold standards and silver linings (2004) (17)
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft (2007) (17)
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. (2002) (16)
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts. (2017) (16)
Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma (2015) (15)
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (2018) (15)
Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects (2004) (15)
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer (2022) (14)
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. (2019) (14)
Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT (2008) (14)
Predominant or complete recipient T‐cell chimerism following alemtuzumab‐based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure (2012) (14)
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update (2014) (13)
Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring (2000) (13)
Post-transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion (2003) (12)
Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy (2004) (12)
PD-1 blockade: promoting endogenous anti-tumor immunity (2012) (12)
Cytomegalovirus-specific T-cell therapies: current status and future prospects. (2015) (12)
An antitumor boost to TH9 cells (2014) (11)
Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma. (2002) (11)
Mini‐BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory DLBCL (2012) (11)
Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. (2012) (10)
The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. (2018) (10)
Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? (2016) (10)
Immunotherapy: opportunities, risks and future perspectives. (2014) (9)
Autologous stem cell transplantation remains beneficial for patients relapsing after R‐CHOP chemotherapy and who respond to salvage chemotherapy (2012) (9)
CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion. (2004) (9)
Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? (2018) (9)
Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy (2015) (9)
Clinical implications of immune reconstitution following hematopoietic stem cell transplantation. (2009) (8)
The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. (2007) (8)
Immunity Report Fc-Optimized Anti-CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (2017) (8)
CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT (2014) (8)
Role of allogeneic stem cell transplantation in multiple myeloma (2005) (7)
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation (2015) (7)
Sociodemographic and psychological determinants of influenza vaccine intention among recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model (2018) (7)
Cytomegalovirus infection and disease after autologous peripheral blood stem cell transplantation (2001) (7)
The evolution of lung cancer and impact of subclonal selection in TRACERx (2023) (7)
Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring. (2000) (7)
ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies (2020) (6)
Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center (2020) (6)
Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. (2021) (6)
ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma. (2016) (6)
CMV-Specific T-Cell Therapy Improves Immune Reconstitution Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial (2014) (6)
Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation. (2009) (6)
Genomic–transcriptomic evolution in lung cancer and metastasis (2023) (6)
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM (2016) (6)
Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation (2020) (6)
Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes (2017) (6)
Allogeneic transplantation in the UK: an aggregation of marginal gains? (2013) (6)
The evolution of non-small cell lung cancer metastases in TRACERx (2023) (6)
Successful translation and future prospects of TALEN editing for leukemia patients (2018) (5)
Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation (2017) (5)
AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL (2019) (5)
Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL) (2004) (5)
Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles (2016) (5)
Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia. (2001) (4)
Cell therapy for cytomegalovirus infection (2020) (4)
Current practice in vitamin D management in Allogeneic Haematopoietic Stem Cell Transplantation: a survey by the Transplant Complications Working Party of the EBMT. (2019) (4)
Role of MabCampath in allogeneic transplantation. (2004) (4)
Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). (2002) (4)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA (2023) (4)
Reduced intensity transplantation: where are we now? (2004) (4)
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. (2019) (4)
Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder (2009) (4)
Adoptive Cellular Therapy for Cytomegalovirus Following Allogeneic Stem Cell Transplantation: Toxicity and Efficacy. (2004) (3)
Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control (2020) (3)
Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080) (2016) (3)
Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts (2017) (3)
Adoptive Transfer of CMV-Specific Donor T Cells Following Allogeneic Transplantation Leads to Rapid and Safe Systemic Reconstitution. (2009) (3)
Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting (2021) (3)
Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion (2019) (3)
Abstract 3143: A novel approach to deplete Treg cells using non-IL-2 blocking anti-CD25-targeting antibodies leads to complete rejection of established tumors (2018) (3)
Recent advances in antibody‐based therapies for Hodgkin Lymphoma (2015) (3)
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (2022) (3)
Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma (2011) (3)
455. Automated Lentiviral Transduction of T Cells with CARS Using the CliniMACS Prodigy (2016) (3)
Emerging options for the treatment of melanoma – focus on ipilimumab (2014) (3)
Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study (2018) (3)
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function (2019) (3)
Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle (2015) (3)
Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (3)
Cytomegalovirus-specific adoptive cellular therapy results in massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation following allogeneic transplantation. (2001) (3)
Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET) (2018) (3)
reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem (2008) (3)
Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH) (2015) (3)
Adoptive Cellular Therapy: A Therapeutic Reality? (2002) (3)
Attack of the T-cell clones. (2013) (3)
Lung adenocarcinoma promotion by air pollutants (2023) (3)
Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia (2019) (2)
AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY (2011) (2)
Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma. (2004) (2)
Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy. (2019) (2)
Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma (2014) (2)
Systematic evaluation of the immune microenvironment of neuroendocrine tumours (2017) (2)
TARGETING THE T‐CELL RECEPTOR Β‐CONSTANT DOMAIN FOR IMMUNOTHERAPY OF T‐CELL MALIGNANCIES (2017) (2)
CAMPATH-1H-containing nonmyeloablative allogeneic stem cell transplantation for myeloma results in delayed T cell reconstitution and a high incidence of viral infections, but low infection-related mortality. (2001) (2)
Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange. (2021) (2)
A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant. (2019) (2)
REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080) (2016) (2)
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report (2021) (2)
Reduced Intensity Allogeneic Transplantation for Non-Hodgkin’s Lymphoma: Extended Follow-Up of an Alemtuzumab-Containing Regimen. (2005) (2)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (2)
Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors (2022) (1)
CMV-Specific T cell Immunotherapy Promotes Restoration of Durable Functional Immunity in High Risk Patients Following Allogeneic Stem Cell Transplantation (2008) (1)
Donor lymphocyte infusion in bone marrow transplantation therapy (2002) (1)
Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx (2023) (1)
Natural history of EBV replication and viral load dynamics after alemtuzumab based allogeneic stem cell transplantation. (2021) (1)
COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation (2021) (1)
Tumor-Associated Antigen Presentation by γδ T-Cells in Cancer Immunotherapy (2014) (1)
REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE (2011) (1)
Comparison between anti-thymocyte globulin and alemtuzumab as part of the melphalan/fludarabine dose-reduced conditioning followed by HLA-matched and mismatched unrelated stem cell transplantation in patients with lymphoid malignancies (2004) (1)
Astrovirus Infection in an Immunocompromised Adult With Encephalitis by Unbiased Next-Generation Sequencing (2015) (1)
Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies (2016) (1)
Excess Late Gastrointestinal Toxicity Associated with Leam Conditioning Compared to BEAM for Autologous Stem Cell Transplantation in Lymphoma, a Single Institution Experience (2014) (1)
Dose-Escalated Donor Lymphocyte Infusions Post Allogeneic Transplantation in Non-Hodgkin’s Lymphoma. (2005) (1)
Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HMI.24. (2003) (1)
Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence. (2018) (1)
Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure (2011) (1)
Trafficking of CAR T cells to sites of subclinical leukaemia cutis. (2020) (1)
Abstract 2787: Generation of first-in-class anti-CD25 antibodies depleting Treg without interfering with IL2 signalling for cancer therapies (2018) (1)
Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients: A British Society for Haematology Good Practice Paper (2021) (1)
A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture. (2022) (1)
Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study (2017) (1)
Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT (2019) (1)
Biomarkers of Response to Immune Modulatory Therapies in Cancer (2015) (1)
Extended follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for follicular lymphoma (2007) (1)
The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: QUALITY MANAGEMENT GROUP — POSTER SESSION (2018) (1)
Brentuximab Vedotin for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a report from the EBMT Lymphoma Working Party (2020) (0)
Tumor-Associated Antigen Presentation by gamma delta T-Cells in Cancer Immunotherapy (2014) (0)
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (2022) (0)
Regulatory TCells Restrain Interleukin-2- andBlimp- 1-Dependent Acquisition of Cytotoxic Function by CD4 T Cells (2020) (0)
Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies (2022) (0)
Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies (2011) (0)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (2020) (0)
A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning (2011) (0)
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON). (2021) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
Abstract A127: Innate crosstalk between ILC and interstitial macrophages promotes lung cancer regression in response to IL-12 therapy (2016) (0)
Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy. (2008) (0)
Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation (2008) (0)
A Prospective Observational Study to Evaluate a Cytomegalovirus (CMV)-Specific Enzyme-Linked Immunospot (Elispot) Assay in Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients: The REACT Study (2017) (0)
UK Cost-Effectiveness Analysis for Management of CMV Disease in Patients Post Allogeneic Stem Cell Transplantation with a Novel Adoptive T Cell Therapy (2016) (0)
The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation. (2004) (0)
The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts (2017) (0)
Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf” (2018) (0)
Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active. (2008) (0)
dendritic cells repertoire diversity following in vitro restimulation by antigen-pulsed specific CD8+ T-cell - Characterization of human cytomegalovirus peptide (2013) (0)
Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD. (2020) (0)
To the editor: CD34 (cid:1) cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion (2003) (0)
The Extended CD 28 : B 7 Immunoglobulin Superfamily (2007) (0)
Abstract B179: Enhancing intratumoural Treg depletion through antibody engineering and analysis of the checkpoint landscape of mouse and human cancers (2016) (0)
Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial. (2022) (0)
Etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) can cytoreduce resistant myeloma patients and mobilise them for transplant without adverse effects. (2003) (0)
Neoantigen-directed immune escape in lung cancer evolution (2019) (0)
Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID) (2016) (0)
P03.30 Tumur mutations drive dysfunctional T cell differentiation in lung cancer (2020) (0)
De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing. (2006) (0)
Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT (2018) (0)
Improving cellular therapies in Epstein – Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulators (2006) (0)
lymphoma transplantation regimen for relapsed and refractory non-Hodgkin Outcomes after alemtuzumab-containing reduced-intensity allogeneic (2008) (0)
The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients (2017) (0)
Donor lymphocyte infusion following reduced intensity allografting (2002) (0)
Long-term follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for aggressive non-Hodgkins lymphoma (2007) (0)
The role of alemtuzumab in allogeneic stem cell transplantation (2005) (0)
Allografting in Hodgkin Lymphoma: SCT Strategies (2014) (0)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (2020) (0)
Checkpoint Blockade and Combinatorial Immunotherapies (2007) (0)
Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTMmanufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use (2020) (0)
The Impact of Donor HLA Type on Characteristics of CMV-Specific T Cell Products: Experience from Two UK Randomized Trials (2014) (0)
Outcome of allogeneic stem cell transplantation in adults with high-risk myeloid malignancies using an alemtuzemab based reduced-intensity-conditioning regimen (2004) (0)
Agonistic anti-ICOS antibodies promote unexpected elimination of tumor infiltrating effector T cells in a FcγR-independent manner (2020) (0)
Impaired T cell reconstitution following high dose therapy supported with CD34+ selected or unselected peripheral blood stem cells in patients with multiple myeloma. (1998) (0)
Abstract A192: Non-IL-2 blocking anti-CD25-targeting antibodies: depletion of regulatory T-cells driving optimal effector response for rejection of established tumors (2019) (0)
Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation (2022) (0)
Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) (2021) (0)
The role of PET scanning in directing immune manipulations following reduced intensity transplants in adults with lymphoid malignancies. (2004) (0)
T-cell depletion CD34+ cell dose and the occurrence of GVHD in the presence of in vivo (2013) (0)
Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD (2013) (0)
P03.23 Evolution of the immune landscape within partially controlled murine melanoma (2020) (0)
Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response (2023) (0)
Centralized production and distribution of CMV-specific cytotoxic T cell lymphocytes ready for commercialization (2013) (0)
A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma (2003) (0)
Abstract A101: Single-cell analysis reveals the pivotal role of the innate immune compartment in aCTLA-4 antitumor response (2020) (0)
Body composition and lung cancer-associated cachexia in TRACERx (2023) (0)
First International Workshop on the Biology , Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
Adoptive immunotherapy for patients with chronic lymphocytic leukaemia using a chimeric antigen receptor targeting CD23 (2011) (0)
Abstract 1508: Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program (2021) (0)
Allogeneic stem cell transplantation for high-risk acute myeloid leukemia: No increase in relapse with alemtuzumab-depleted grafts. (2005) (0)
Current practice in vitamin D assessment and management across the Adult and Paediatric Haematopoietic Stem Cell Transplant Centres in Europe: a survey by the Transplant Complications Working Party of the EBMT (2020) (0)
Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma (2011) (0)
Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells (2018) (0)
NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry (2020) (0)
Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM). (2016) (0)
Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation. (2008) (0)
ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (2021) (0)
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (2020) (0)
nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following (2013) (0)
Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma (2003) (0)
Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation (2018) (0)
Clinical implications of immune reconstitution following autologous and allogeneic transplantation. (2009) (0)
A Comparison of Stem Cell Source in Recipients of T-Cell Depleted Myeloablative Transplants for Leukaemia: No Difference in Mortality Using BM or PBSC. (2007) (0)
Lymphocyte morphology in a patient receiving CD19 chimeric antigen receptor T‐cell therapy for mantle cell lymphoma (2021) (0)
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (2020) (0)
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma. (2023) (0)
Consensus Grading for Cytokine Release Syndrome and Neurologic D 224 X X Toxicity Associated with Immune Effector Cells (2019) (0)
Generation of T-cell mediated immune responses to the myeloma antigen, HM1.24. (2002) (0)
7ODeciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study (2017) (0)
T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study (2019) (0)
Defining The Optimal Dose Of Alemtuzumab In Unrelated Donor Reduced Intensity Allografts: A UK Retrospective Study (2013) (0)
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy. (2021) (0)
Life after allogeneic bone marrow transplant. (2012) (0)
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (2020) (0)
Dissociation of Systemic and Local Anti-Tumor Immunity Following Depletion of Regulatory T Cells Limits Therapeutic Activity in Established Tumors. (2007) (0)
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation (2015) (0)
Association of the imbalance between early and late differentiated intra-tumor CD4 T cells with mutational burden in non-small cell lung cancer. (2019) (0)
Favorable outcomes in elderly and high-risk patients with AML and MDS following T-cell depleted reduced intensity conditioned allogeneic stem cell transplantation (2012) (0)
Advanced T-Cell Engineering for Cancer Therapy (ATECT). (2015) (0)
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA - OUTCOMES FROM A SINGLE ACADEMIC CENTRE: PF488 (2019) (0)
Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation (2007) (0)
A characterization of cytotoxic CD4+ T lymphocytes in Chronic Lymphocytic Leukemia (CLL) and the identification of their presence in the tumor microenvironment (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Karl S. Peggs?

Karl S. Peggs is affiliated with the following schools: